LRRC32 Antikörper (APC)

Produktnummer ABIN2658317

Dieses Anti-LRRC32-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von LRRC32 in BCA. Geeignet für Human.

Kurzübersicht für LRRC32 Antikörper (APC) (ABIN2658317)

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser LRRC32 Antikörper ist konjugiert mit APC

Applikation: Biochemical Assay (BCA)

Klon: 7B11

Produktdetails anti-LRRC32 Antikörper (APC)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

Isotyp: IgG2b kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu LRRC32

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Andere Bezeichnung: GARP

Hintergrund: Glycoprotein A Repetitions Predominant (GARP), also known as leucine rich repeat containing 32 (LRC32), is a 80 kD type I membrane glycoprotein with 20 leucine rich repeats in the extracellular portion of the protein. GARP was found on the surface of megakaryocytes, platelets, and activated Tregs (CD4+, CD25+, FoxP3+ cells) and serves as a receptor for latent TGF-β. Recent evidence suggests that GARP may play a role in controlling suppressor function of Tregs. A mutation in GARP has been reported in a large Samaritan kindred with Usher syndrome type 1, an autosomal recessive disease characterized by profound congenital sensorineural deafness, vestibular dysfunction, and progressive visual loss. In addition, it has been found that GARP mRNA is highly amplified in different tumors, which indicates that tumor cells may use GARP to express TGF-β or to capture TGF-β from their surroundings, resulting in local suppression of anti-tumor immune responses or the induction of Tregs.

Pathways: Activated T Cell Proliferation